Wealth Enhancement Advisory Services LLC Cuts Position in Repligen Corporation $RGEN

Wealth Enhancement Advisory Services LLC trimmed its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 4.7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,926 shares of the biotechnology company’s stock after selling 192 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Repligen were worth $500,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of RGEN. Twin Tree Management LP purchased a new stake in shares of Repligen during the 1st quarter valued at $29,000. Signaturefd LLC grew its position in Repligen by 65.3% during the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 128 shares during the period. Center for Financial Planning Inc. grew its position in Repligen by 110.3% during the first quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 193 shares during the period. UMB Bank n.a. increased its holdings in Repligen by 99.4% during the first quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company’s stock worth $85,000 after buying an additional 332 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in Repligen by 40.1% in the first quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 274 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Repligen Trading Up 2.4%

NASDAQ RGEN opened at $148.73 on Monday. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. The stock’s 50-day simple moving average is $122.38 and its two-hundred day simple moving average is $125.28. Repligen Corporation has a twelve month low of $102.96 and a twelve month high of $182.52. The company has a market capitalization of $8.37 billion, a price-to-earnings ratio of -594.90, a PEG ratio of 2.74 and a beta of 1.08.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). The firm had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. Repligen’s revenue for the quarter was up 14.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Research analysts forecast that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on RGEN shares. HSBC started coverage on shares of Repligen in a research note on Wednesday. They set a “buy” rating and a $150.00 price target for the company. Hsbc Global Res raised Repligen to a “strong-buy” rating in a research report on Wednesday, October 1st. Wells Fargo & Company lowered their target price on Repligen from $180.00 to $175.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 30th. Evercore ISI upgraded Repligen from an “in-line” rating to an “outperform” rating and increased their price target for the stock from $130.00 to $155.00 in a research note on Monday, September 22nd. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research note on Tuesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $168.08.

Insider Activity at Repligen

In other Repligen news, Director Martin D. Madaus acquired 1,800 shares of the stock in a transaction dated Friday, August 8th. The stock was purchased at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the acquisition, the director owned 1,800 shares in the company, valued at $201,834. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 1.20% of the company’s stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.